1) RNAi-based drugs
RNAi类药物
1.
RNAi-based drugs have made great progress in extensive therapeutic areas.
目前RNAi类药物的研究已在多种疾病治疗领域取得了较好进展。
2) RNAi reagent
RNAi药物
3) RNA interference
RNAi
1.
F10 gene knock-down mediated by RNA interference induces apoptosis of KLE cells;
RNAi下调F10基因表达对KLE细胞凋亡的影响
2.
Effects of HMGA1 silence by RNA interference on the apoptosis and cell cycle of hepatocarcinoma cells;
RNAi沉默HMGA1基因对肝癌细胞凋亡和细胞周期的影响
3.
Effect of inhabitation of VEGF expression with RNA interference on lung cancer therapy
RNAi沉默VEGF的表达及其治疗肺癌的初步研究
5) animal-like drugs
动物类药
1.
This article tries to introduce professor Zhou Zhongying’s clinical experience in the treatment of obstinate diseases from the perspectives of the property of animal-like drugs and its clinical application.
通过总结动物类药物的临床应用方法和使用要点,结合验案分析,介绍周仲瑛教授运用动物类药物治疗疑难杂症的临床经验。
6) Platinum
[英]['plætɪnəm] [美]['plætṇəm]
铂类药物
1.
Expression of ERCC1 and the correlation with platinum-based chemotherapy sensitivity and clinical significance in the advanced non-small cell lung cancer
晚期非小细胞肺癌组织中ERCC1表达与铂类药物化疗敏感性关系及其临床意义
2.
Nucleotide excision repair genetic polymorphisms and resistance of platinum
核苷酸切除修复基因多态性和铂类药物耐药性关系研究进展
3.
Objective: To investigate the expression of ERCC1 and the correlation with platinum-based chemotherapy sensitivity in advanced non-small cell lung cancer (NSCLC) as well as its clinical prognostic significance.
结论:ERCC1表达不同是晚期NSCLC患者化疗方案中铂类药物敏感性差别的重要因。
补充资料：[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式：C16H16ClN3O3S
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条